A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma

著者: Neha Korde, Mattias Carlsten, M.-J. Lee, Amanda Minter, Eng M. Tan, Mary Kwok, Elisabet E. Manasanch, Manisha Bhutani, Nishant Tageja, Mark Roschewski, Adriana Zingone, Rene Costello, Marcia Mulquin, Diamond Zuchlinski, I. Maric, Katherine R. Calvo, Raul C. Braylan, Prashant Tembhare, Constance M. Yuan, Maryalice Stetler‐Stevenson, Jane B. Trepel, Richard Childs, Ola Landgren - Haematologica 2014 被引用: 127

Natural killer (NK) cells are involved in immune surveillance of various malignancies, including multiple myeloma (MM).[1][1] IPH2101 is a fully human monoclonal antibody that blocks HLA-C binding KIR2D receptors (KIR2DL/DS-1, -2 -3) expressed on the surface of NK-cells, enhancing their cytotoxicity